ストックスクリーナーアプリを入手
134.36
2.96%
3.86
アフターアワーズ：
134.36
前日終値:
$130.50
開ける：
$131.57
24時間の取引高:
5.97M
Relative Volume:
0.99
時価総額：
$166.82B
収益：
$29.79B
当期純損益:
$9.22B
株価収益率:
18.28
EPS:
7.3494
ネットキャッシュフロー:
$10.23B
1週間 パフォーマンス:
+3.69%
1か月 パフォーマンス:
+1.10%
6か月 パフォーマンス:
+6.10%
1年 パフォーマンス:
+25.88%
1日の値動き範囲:
$131.12
$134.52
1週間の範囲:
$128.34
$134.52
52週間の値動き範囲:
$104.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, MRK, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
134.36 | 162.02B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,065.00 | 928.88B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.34 | 557.82B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.70 | 378.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
122.41 | 286.20B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.03 | 294.27B | 60.48B | 10.40B | 8.05B | 3.3297 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Maxim Upgrades Gilead Sciences (GILD) to ‘Buy’ - Insider Monkey
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference - MarketBeat
Axxcess Wealth Management LLC Has $4.44 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Gilead Sciences leans on HIV growth as deals build oncology, inflammation pipeline - MSN
LSV Asset Management Has $508.91 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Global Retirement Partners LLC Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price Gains - Yahoo Finance
Gilead Sciences Inc. (NASDAQ: GILD) Holds Steady as HIV and Oncology Portfolio Drives Income - foreignpolicyjournal.com
Gilead Sciences Inc Stock (GILD) Closed Up by 3.04% on May 22: Drivers Behind the Movement - TradingKey
Gilead wins FDA approval for first hepatitis delta treatment By Investing.com - Investing.com Nigeria
Gilead's drug wins first-ever US approval for deadly liver infection - Reuters
GILD Stock Jumps After Winning Accelerated FDA Approval For HDV Treatment - Yahoo Finance
US FDA approves Gilead's drug for deadly liver infection - Yahoo
Gilead Sciences stock rises after FDA approves HDV treatment - Investing.com
New Gilead shot is first FDA-approved treatment for deadly hepatitis D - Stock Titan
Gilead Sciences stock rises after FDA approves HDV treatment By Investing.com - Investing.com Canada
(bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) - Business Wire
GILD: Gilead's Trodelvy Gains Positive Opinion for TNBC Treatmen - GuruFocus
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $180 - Moomoo
Gilead Wins CHMP Positive Opinion for Breast Cancer Drug Trodelvy - Moomoo
GILD Receives Positive EMA Opinion for Trodelvy in Breast Cancer Treatment - GuruFocus
Gilead’s Trodelvy receives EU committee backing for breast cancer By Investing.com - Investing.com Australia
Gilead inks $140M API supply deal, tightening ties to Korean manufacturer - BioSpace
in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors - Business Wire
Keudell Morrison Wealth Management Purchases Shares of 16,022 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences acquires Tubulis for $5bn - Yahoo Finance
Gilead Sciences completes Tubulis acquisition for $5bn - Pharmaceutical Technology
Zacks Research Forecasts Weaker Earnings for Gilead Sciences - MarketBeat
PNC Financial Services Group Inc. Has $58.19 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Northwestern Mutual Wealth Management Co. Buys 13,252 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Key facts: Gilead buys Tubulis for $3.15B; remdesivir vs Bundibugyo - TradingView
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology - BioSpace
Return on assets % of Gilead Sciences, Inc. – BVL:GILDUS - TradingView
Fidelity Low-Priced Stock K6 Fund's Gilead Sciences Inc(GILD) Holding History - GuruFocus
ETFs Investing in Gilead Sciences, Inc. Stocks - TradingView
Gilead Sciences, Inc. completed the acquisition of Tubulis GmbH from a group of shareholders. - marketscreener.com
Gilead Sciences, Inc. Cash Flow – BVL:GILDUS - TradingView
Gilead Sciences, Inc. Revenue Breakdown – BVL:GILDUS - TradingView
Gilead Sciences (GILD) Is Among The Best Extremely Profitable Stocks To Buy According To Wall Street Analysts - Yahoo Finance
Gilead pledges 400K AmBisome doses to fight visceral leishmaniasis in expanded WHO collab - Fierce Pharma
Gilead Sciences Completes Acquisition of Tubulis - Contract Pharma
Why Gilead Sciences Is Now A Hold (Rating Upgrade) (NASDAQ:GILD) - Seeking Alpha
Gilead completes $3.15 billion acquisition of Tubulis By Investing.com - Investing.com Canada
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio - Business Wire
Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now - Yahoo Finance
Gilead Renews WHO Partnership to Fight Deadly Kala-Azar - Contract Pharma
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease - BioSpace
Leonteq Securities AG Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences extends WHO partnership to fight visceral leishmaniasis - StreetInsider
400,000 drug vials to fight a fatal parasite in 74% of VL hotspots - Stock Titan
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
May 15 '26 |
Option Exercise |
66.64 |
25,000 |
1,666,000 |
153,779 |
| Mercier Johanna | Chief Comm & Corp Aff Officer |
May 15 '26 |
Sale |
131.29 |
28,000 |
3,676,199 |
125,779 |
0.56%
0.19%
大文字化:
|
ボリューム (24 時間):